Status:

COMPLETED

Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA

Lead Sponsor:

Boehringer Ingelheim

Conditions:

Venous Thromboembolism

Eligibility:

All Genders

18+ years

Brief Summary

Observational cohort study on the prevention of venous thromboembolic events after elective orthopaedic surgery for Total Knee Replacement or Total Hip Replacement iin patients treated with PRADAXA to...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Patients treated with Pradaxa undergoing surgery for Total Knee Replacement or Total Hip Replacement
  • Patients 18 years of age or older at the time of recruitment
  • Exclusion criteria:
  • Patients presenting contraindication to prescription of Pradaxa
  • Patients in whom long term Anti vitamin K treatment is indicated

Exclusion

    Key Trial Info

    Start Date :

    August 1 2010

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    September 1 2012

    Estimated Enrollment :

    1676 Patients enrolled

    Trial Details

    Trial ID

    NCT01139658

    Start Date

    August 1 2010

    End Date

    September 1 2012

    Last Update

    January 16 2014

    Active Locations (53)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 14 (53 locations)

    1

    Boehringer Ingelheim Investigational Site 30

    Angers, France

    2

    Boehringer Ingelheim Investigational Site 41

    Arles, France

    3

    Boehringer Ingelheim Investigational Site 40

    Beauvais, France

    4

    Boehringer Ingelheim Investigational Site 2

    Berck, France